HC Wainwright Increases Earnings Estimates for BioCardia

BioCardia, Inc. (NASDAQ:BCDA) – Equities researchers at HC Wainwright raised their FY2024 EPS estimates for shares of BioCardia in a research report issued on Thursday, November 14th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of ($3.52) for the year, up from their prior forecast of ($5.06). HC Wainwright currently has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for BioCardia’s current full-year earnings is ($3.52) per share. HC Wainwright also issued estimates for BioCardia’s Q4 2024 earnings at ($0.87) EPS, FY2025 earnings at ($1.22) EPS, FY2026 earnings at ($1.33) EPS, FY2027 earnings at ($1.42) EPS and FY2028 earnings at ($1.03) EPS.

BioCardia Price Performance

Shares of BCDA stock opened at $1.85 on Monday. The company has a market cap of $3.92 million, a PE ratio of -0.44 and a beta of 1.28. The stock’s 50 day simple moving average is $2.58 and its two-hundred day simple moving average is $3.30. BioCardia has a 1 year low of $1.84 and a 1 year high of $14.40.

About BioCardia

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.